These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27343044)

  • 1. VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice.
    Sun M; Li Y; Yuan Z; Lu W; Kang G; Fan W; Li Q
    Arch Virol; 2016 Sep; 161(9):2449-55. PubMed ID: 27343044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.
    Astronomo RD; Lemos MP; Narpala SR; Czartoski J; Fleming LB; Seaton KE; Prabhakaran M; Huang Y; Lu Y; Westerberg K; Zhang L; Gross MK; Hural J; Tieu HV; Baden LR; Hammer S; Frank I; Ochsenbauer C; Grunenberg N; Ledgerwood JE; Mayer K; Tomaras G; McDermott AB; McElrath MJ
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34166231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.
    Veselinovic M; Neff CP; Mulder LR; Akkina R
    Virology; 2012 Oct; 432(2):505-10. PubMed ID: 22832125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
    Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
    PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing monoclonal antibodies for HIV prevention.
    Miner MD; Corey L; Montefiori D
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.
    Zhao C; Gunawardana M; Villinger F; Baum MM; Remedios-Chan M; Moench TR; Zeitlin L; Whaley KJ; Bohorov O; Smith TJ; Anderson DJ; Moss JA
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial.
    Politch JA; Cu-Uvin S; Moench TR; Tashima KT; Marathe JG; Guthrie KM; Cabral H; Nyhuis T; Brennan M; Zeitlin L; Spiegel HML; Mayer KH; Whaley KJ; Anderson DJ
    PLoS Med; 2021 Feb; 18(2):e1003495. PubMed ID: 33534791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques.
    Calenda G; Frank I; Arrode-Brusés G; Pegu A; Wang K; Arthos J; Cicala C; Rogers KA; Shirreff L; Grasperge B; Blanchard JL; Maldonado S; Roberts K; Gettie A; Villinger F; Fauci AS; Mascola JR; Martinelli E
    PLoS Pathog; 2019 May; 15(5):e1007776. PubMed ID: 31083697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.
    Su B; Lederle A; Laumond G; Ducloy C; Schmidt S; Decoville T; Moog C
    J Virol; 2014 Sep; 88(18):10975-81. PubMed ID: 24965460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.
    Chen X; Zhou T; Schmidt SD; Duan H; Cheng C; Chuang GY; Gu Y; Louder MK; Lin BC; Shen CH; Sheng Z; Zheng MX; Doria-Rose NA; Joyce MG; Shapiro L; Tian M; Alt FW; Kwong PD; Mascola JR
    Immunity; 2021 Feb; 54(2):324-339.e8. PubMed ID: 33453152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.
    Cunningham CK; McFarland EJ; Morrison RL; Capparelli EV; Safrit JT; Mofenson LM; Mathieson B; Valentine ME; Perlowski C; Smith B; Hazra R; Purdue L; Muresan P; Harding PA; Mbengeranwa T; Robinson LG; Wiznia A; Theron G; Lin B; Bailer RT; Mascola JR; Graham BS;
    J Infect Dis; 2020 Jul; 222(4):628-636. PubMed ID: 31681963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sensitive method to quantify HIV-1 antibodies in mucosal samples.
    Prabhakaran M; Narpala S; Andrews SF; O'Connell S; Lin CL; Coates EE; Flach B; Ledgerwood JE; McDermott AB
    J Immunol Methods; 2021 Apr; 491():112995. PubMed ID: 33582148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
    Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
    J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge.
    Pardi N; Secreto AJ; Shan X; Debonera F; Glover J; Yi Y; Muramatsu H; Ni H; Mui BL; Tam YK; Shaheen F; Collman RG; Karikó K; Danet-Desnoyers GA; Madden TD; Hope MJ; Weissman D
    Nat Commun; 2017 Mar; 8():14630. PubMed ID: 28251988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
    Corey L; Gilbert PB; Juraska M; Montefiori DC; Morris L; Karuna ST; Edupuganti S; Mgodi NM; deCamp AC; Rudnicki E; Huang Y; Gonzales P; Cabello R; Orrell C; Lama JR; Laher F; Lazarus EM; Sanchez J; Frank I; Hinojosa J; Sobieszczyk ME; Marshall KE; Mukwekwerere PG; Makhema J; Baden LR; Mullins JI; Williamson C; Hural J; McElrath MJ; Bentley C; Takuva S; Gomez Lorenzo MM; Burns DN; Espy N; Randhawa AK; Kochar N; Piwowar-Manning E; Donnell DJ; Sista N; Andrew P; Kublin JG; Gray G; Ledgerwood JE; Mascola JR; Cohen MS;
    N Engl J Med; 2021 Mar; 384(11):1003-1014. PubMed ID: 33730454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors.
    Luo S; Jing C; Ye AY; Kratochvil S; Cottrell CA; Koo JH; Chapdelaine Williams A; Francisco LV; Batra H; Lamperti E; Kalyuzhniy O; Zhang Y; Barbieri A; Manis JP; Haynes BF; Schief WR; Batista FD; Tian M; Alt FW
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2217883120. PubMed ID: 36574685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.
    McFarland EJ; Cunningham CK; Muresan P; Capparelli EV; Perlowski C; Morgan P; Smith B; Hazra R; Purdue L; Harding PA; Theron G; Mujuru H; Agwu A; Purswani M; Rathore MH; Flach B; Taylor A; Lin BC; McDermott AB; Mascola JR; Graham BS;
    J Infect Dis; 2021 Dec; 224(11):1916-1924. PubMed ID: 34009371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.
    Bonsignori M; Scott E; Wiehe K; Easterhoff D; Alam SM; Hwang KK; Cooper M; Xia SM; Zhang R; Montefiori DC; Henderson R; Nie X; Kelsoe G; Moody MA; Chen X; Joyce MG; Kwong PD; Connors M; Mascola JR; McGuire AT; Stamatatos L; Medina-Ramírez M; Sanders RW; Saunders KO; Kepler TB; Haynes BF
    Immunity; 2018 Dec; 49(6):1162-1174.e8. PubMed ID: 30552024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.